Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in NonSmall Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating…Read More